We greatly appreciate the letter from Rios et al. (1) in which they report a lack of association between basal or glucagon-stimulated C-peptide and basophil counts in recently diagnosed type 1 diabetic patients followed for 1 year. This is precisely the type of analysis of other datasets that we hoped to stimulate with our article (2). We are currently evaluating whether the observations reported in our publication can be replicated and extended using new TrialNet data. Such iterative work will allow for exploring how robust the observations are and further to examine whether there are factors other than chance that may explain any differences observed.
No potential conflicts of interest relevant to this article were reported.
I. Comment on: Greenbaum et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2066–2073 (Letter).
e7. DOI: 10.2337/db13-0047
D, et al.;
Type 1 Diabetes TrialNet Study Group.
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
© 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.